A Single-Center, Randomized, Partially Double-Blind, Placebo- and Active-Controlled, Four-period Crossover, Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

This is a single-center, randomized, partially double-blind, placebo and active-controlled, 4-period crossover design thorough QT/QTc (TQT) clinical study to evaluate the effects of ziresovir on cardiac repolarization in healthy subjects.

Start Date15 Sep 2024

Sponsor / Collaborator

Shanghai Ark Biopharmaceutical Co., Ltd.Startup

CTR20240557

/ RecruitingPhase 3

一项在呼吸道合胞病毒感染的住院婴幼儿中评价多次口服AK0529的有效性、安全性、耐受性和抗病毒作用的随机、双盲、安慰剂对照的III期确认性研究

[Translation] A randomized, double-blind, placebo-controlled, Phase III confirmatory study to evaluate the efficacy, safety, tolerability, and antiviral effects of multiple oral doses of AK0529 in hospitalized infants and young children with respiratory syncytial virus infection

确认AK0529治疗在毛细支气管炎临床评分较基线的变化上优于安慰剂。评估AK0529抗病毒效力。

[Translation]

Confirm that AK0529 treatment is superior to placebo in the change from baseline in bronchiolitis clinical scores. Evaluate the antiviral efficacy of AK0529.

Start Date29 Feb 2024

Sponsor / Collaborator

Shanghai Ark Biopharmaceutical Co., Ltd.Startup

NCT06775405

/ RecruitingPhase 3

A Randomized, Double-blind, Placebo-controlled, Phase III Confirmatory Study to Evaluate the Efficacy, Safety, Tolerability, and Antiviral Activity of Repeated Oral Administration of AK0529 in Hospitalized Infants with Respiratory Syncytial Virus Infection

Respiratory syncytial virus (RSV) is the most common respiratory infectious pathogen recognized worldwide that poses serious health risks to infants, and an important cause of hospitalization for severe respiratory infections in infants. Serious respiratory problems such as pneumonia caused by RSV are one of the leading causes of death from respiratory diseases in infants. AK0529 targets the Pre-F (fusion) protein on the surface of the viral envelope. Specifically, it prevents the virus from invading uninfected cells and inhibits the fusion between host cells by inhibiting the fusion of the F (fusion) proteins on the surface of the RSV envelope, thus providing the effects of anti-RSV infection. This is a randomized, double-blind, placebo-controlled, multicenter, phase III clinical study to evaluate the efficacy and safety of AK0529 in hospitalized infants aged 1 to 24 months with RSV infection. Considering the benefits of AK0529 in the population with RSV infection, hospitalized infants with moderate to severe RSV infection were selected as the target population for this study.

Start Date29 Feb 2024

Sponsor / Collaborator

Shanghai Ark Biopharmaceutical Co., Ltd.Startup

100 Clinical Results associated with Ziresovir

100 Translational Medicine associated with Ziresovir

100 Patents (Medical) associated with Ziresovir

Literatures (Medical) associated with Ziresovir

01 Jan 2025·Vaccine

Cost-effectiveness of anti-viral treatment for infants with RSV disease in the United Kingdom

Article

Author: Gebrecherkos, Yonas ; Hodgson, David

BACKGROUNDRespiratory Syncytial Virus (RSV) is a common cause of hospitalisation in infants worldwide, causing significant morbidity and mortality. Recently, the antiviral treatment, Ziresovir, has shown promising results in a Phase III trial conducted on infants hospitalised with RSV. Based on these topline results, this study aims to investigate the cost-effectiveness of Ziresovir in the United Kingdom (UK).METHODSThe cost-effective analysis (CEA) uses a proportional outcomes model using data from topline reports by the AIRFLO trial and published data to explore the effect of Ziresovir administration on hospitalised infants aged <24 months at admission. We estimated the reduction in ICU bed days and deaths and the maximum cost-effective price (MCEP) per treated individual, assuming a threshold of £20,000 per Quality-adjusted Life Year (QALY) gained.RESULTSAdministering Ziresovir to all hospitalised infants averts four deaths (range: 2.8-4.5), 216 ICU admissions (range:160-260) and 3169 ICU bed-days (range: 2348-3804) per annum, the MCEP for Ziresovir per hospitalised infant is £429.65 (95 % CrI: £236-£771). If preterm infants are targeted, then the MCEP increases to £2108.38 (95 % Crl: £870-£3540). The MCEP for exclusively treating Infants with Chronic Lung Disease (CLD) and Congenital Heart Disease (CHD) is £6557.24 (95 % Crl: £1250 - £14,920) and £9459.44 (95 % Crl £3350-£20,300) respectively. The model is highly sensitive to changes in the efficacy of Ziresovir and the risk of ICU admission and mortality.CONCLUSIONZiresovir is a cost-effective intervention for all infants hospitalised with RSV if priced below £430 per dose and strategies that exclusively treat high-risk- with CLD and CHD infants justify a higher price of £6558 and £9460 respectively. The outcomes are highly sensitive to the efficacy of Ziresovir and can be improved when the full results of the AIRFLO trial are available.

26 Sep 2024·New England Journal of Medicine

Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection

Article

Author: Rito, Ki ; Zhang, Hua ; Zhong, Lili ; Shen, Zhaobo ; Yin, Yong ; Liu, Hanmin ; Deng, Li ; Wu, Yan ; Chen, Qiang ; Yang, Qiaozhi ; Zhao, Deyu ; Shang, Yunxiao ; Jiang, Wenhui ; Xu, Yongsheng ; Wang, Xiufang ; Hao, Chuangli ; Zhou, Wei ; Nong, Guangmin ; Zou, Gang ; Zou, Yingxue ; Chen, Yiping ; Li, Ling ; Yang, Yungang ; Jia, Tan ; Lu, Xiaoxia ; Ni, Xin ; Chen, Zhimin ; Zhang, Hailin ; Zhao, Shunying ; Ding, Rong ; Zhu, Xiaoping ; Huang, Dongming ; Cheng, Huanji ; Liu, Enmei ; Zheng, Yuejie ; Dong, Xiaoyan ; Wu, Jim Z. ; Shen, Tong

BACKGROUNDRespiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the treatment of infants hospitalized with RSV infection.METHODSIn a phase 3, multicenter, double-blind, randomized, placebo-controlled trial conducted in China, we enrolled participants 1 to 24 months of age who were hospitalized with RSV infection. Participants were randomly assigned, in a 2:1 ratio, to receive ziresovir (at a dose of 10 to 40 mg, according to body weight) or placebo, administered twice daily, for 5 days. The primary end point was the change from baseline to day 3 (defined as 48 hours after the first administration) in the Wang bronchiolitis clinical score (total scores range from 0 to 12, with higher scores indicating greater severity of signs and symptoms). The intention-to-treat population included all the participants with RSV-confirmed infection who received at least one dose of ziresovir or placebo; the safety population included all the participants who received at least one dose of ziresovir or placebo.RESULTSThe intention-to-treat population included 244 participants, and the safety population included 302. The reduction from baseline in the Wang bronchiolitis clinical score at day 3 was significantly greater with ziresovir than with placebo (-3.4 points [95% confidence interval {CI}, -3.7 to -3.1] vs. -2.7 points [95% CI, -3.1 to -2.2]; difference, -0.8 points [95% CI, -1.3 to -0.3]; P = 0.002). The reduction in the RSV viral load at day 5 was greater in the ziresovir group than in the placebo group (-2.5 vs. -1.9 log₁₀ copies per milliliter; difference, -0.6 log₁₀ copies per milliliter [95% CI, -1.1 to -0.2]). Improvements were observed in prespecified subgroups, including in participants with a baseline bronchiolitis score of at least 8 and in those 6 months of age or younger. The incidence of adverse events related to the drug or placebo was 16% with ziresovir and 13% with placebo. The most common adverse events that were assessed by the investigator as being related to the drug or placebo were diarrhea (in 4% and 2% of the participants, respectively), an elevated liver-enzyme level (in 3% and 3%, respectively), and rash (in 2% and 1%). Resistance-associated mutations were identified in 15 participants (9%) in the ziresovir group.CONCLUSIONSZiresovir treatment reduced signs and symptoms of bronchiolitis in infants and young children hospitalized with RSV infection. No safety concerns were identified. (Funded by Shanghai Ark Biopharmaceutical; AIRFLO ClinicalTrials.gov number, NCT04231968.).

01 Sep 2024·Reviews in Medical Virology

Systematic Review of the Efficacy and Safety of RSV‐Specific Monoclonal Antibodies and Antivirals in Development

Review

Author: Sevendal, Andrea T. K. ; Hurley, Siobhan ; Walker, Gregory J. ; Bartlett, Adam W. ; Rawlinson, William

ABSTRACTRespiratory syncytial virus (RSV) is a leading cause of acute respiratory infection amongst all ages, causing a significant global health burden. Preventative and therapeutic options for RSV infection have long been under development, and recently, several widely‐publicised vaccines targeting older adult and maternal populations have become available. Promising monoclonal antibody (mAb) and antiviral (AV) therapies are also progressing in clinical trials, with the prophylactic mAb nirsevimab recently approved for clinical use in infant populations. A systematic review on current progress in this area is lacking. We performed a systematic literature search (PubMed, Embase, Web of Science, ClinicalTrials.gov, EudraCT, ANZCTR—searched Nov 29th, 2023) to identify studies on all RSV‐specific mAbs and AV therapies that has undergone human clinical trials since year 2000. Data extraction focused on outcomes related to the therapeutic efficacy and safety of the intervention on trial, and all studies were graded against the OCEBM Levels of Evidence Table. Results from 59 studies were extracted, covering efficacy and safety data on six mAbs (motavizumab, motavizumab‐YTE, nirsevimab, ALX‐0171, suptavumab, clesrovimab) and 12 AV therapies (ALN‐RSV01, RSV604, presatovir, MDT‐637, lumicitabine, IFN‐α1b, rilematovir, enzaplatovir, AK0529, sisunatovir, PC786, EDP‐938). Of the mAbs reviewed, nirsevimab and clesrovimab hold considerable promise. The timeline for RSV‐specific AV availability is less advanced, although EDP‐938 and AK0529 have reported promising phase 2 efficacy and safety data. Moving forward, passive immunisation and treatment options for RSV infection will play a significant role in reducing the health burden of RSV, complementing recent advancements in vaccine development.Trial RegistrationPROSPERO registration: CRD42022376633

News (Medical) associated with Ziresovir

27 Sep 2024

·www.drugs.com

Ziresovir Reduces Signs, Symptoms of Bronchiolitis in Babies With RSV

FRIDAY, Sept. 27, 2024 -- For infants and young children hospitalized with respiratory syncytial virus (RSV) infection, ziresovir reduces signs and symptoms of bronchiolitis, according to a study published in the Sept. 26 issue of the New England Journal of Medicine . Shunying Zhao, M.D., Ph.D., from Beijing Children's Hospital, and colleagues enrolled participants aged 1 to 24 months of age who were hospitalized with RSV infection in a phase 3, multicenter trial. Participants were randomly assigned to receive ziresovir (10 to 40 mg according to body weight) or placebo, administered twice daily for five days in a 2:1 ratio. A total of 244 participants were included in the intention-to-treat population, and the safety population included 302 participants. The researchers observed a significantly greater reduction from baseline in the Wang bronchiolitis clinical score at day 3 with ziresovir than with placebo (−3.4 versus −2.7 points). At day 5, the reduction in the RSV viral load was greater in the ziresovir group than the placebo group (−2.5 versus −1.9 log 10 copies/mL). Prespecified subgroups, including those with a baseline bronchiolitis score of at least 8 and those aged 6 months or younger, showed improvements. The incidence rates of adverse events related to the drug or placebo were 16 and 13 percent, respectively. "Ziresovir treatment in infants and young children who were hospitalized with RSV infection resulted in a significantly greater resolution of signs and symptoms associated with RSV infection as well as greater decrease in the viral load than placebo," the authors write. The study was funded by Shanghai Ark Biopharmaceutical, which is developing ziresovir.

Phase 3Clinical Result

07 Oct 2022

·www.fiercebiotech.com

With China filing in its sights, ArkBio shares more phase 3 data on ex-Roche antiviral in RSV

In April, ArkBio outlined plans to file for approval in China around the middle of the year. Ark Biopharmaceutical has shared a closer look at the data it hopes will secure approval of its antiviral ziresovir in the treatment of respiratory syncytial virus (RSV), linking the candidate to significantly shorter intensive care stays and reduced wheezing in the months after treatment. Shanghai-based ArkBio entered the RSV race in 2014 by striking a deal for ziresovir, a RSV fusion inhibitor that was discovered by Roche. The biotech guided the candidate through early and mid-phase trials, leading to the delivery of top-line data from a pivotal study in April. The data drop revealed the phase 3 trial of 311 infants hospitalized with RSV infection hit its primary endpoint, plus a secondary endpoint. ArkBio recently repeated the top-line data at the International RSV Symposium, where it also revealed some figures that were excluded from its original release. The new data covers endpoints that could be important from payer and quality of life perspectives. On the payer front, ArkBio now has evidence that ziresovir reduces the duration of expensive stays in ICUs. Among participants admitted to ICU, the average stay in the ziresovir arm was three days, compared to eight days in the placebo cohort. Linking ziresovir to shorter ICU stays could help ArkBio as it tries to show the pharmacoeconomic value of the therapy to payers and healthcare systems. The latest ArkBio release lacks data on other endpoints with pharmacoeconomic importance. ArkBio originally listed frequency of ICU admission and length of hospital stay as secondary endpoints, although it deleted the latter measure from the ClinicalTrials.gov listing two months after completing the study. The latest release lacks data on either measure. The other new efficacy result reported in the latest release covers the follow-up data that are now available. Over the follow-up period, the rate of wheezing was lower in a subpopulation of children aged under six months who took ziresovir in comparison to their peers on placebo. The difference, 9.0% versus 26.3%, was statistically significant. Wheezing isn’t listed as an endpoint on ClinicalTrials.gov. Upon releasing the top-line data in April, ArkBio outlined plans to file for approval in China around the middle of the year. The latest release lacks an update on the regulatory submission plan.

05 Oct 2015

·www.biospace.com

Ark Biosciences Completes Phase I Trial Of Antivirus Drug

Ark Biosciences, a Shanghai biotech developing proprietary therapeutics for respiratory viral diseases and viral hepatitis, successfully completed a phase I clinical trial of its anti-respiratory syncytial virus (RSV) drug AK0529. The trial is a randomized, double-blind, placebo-controlled study of orally administered AK0529 that evaluates safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses. Ark had completed a Series A round led by Qiming and Morningside in April 2015 to help fund the advancement of AK0529.

100 Deals associated with Ziresovir

External Link

KEGG	Wiki	ATC	Drug Bank
-	Ziresovir	-	DB15145

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Respiratory Syncytial Virus Infections	NDA/BLA	CN	Shanghai Ark Biopharmaceutical Co., Ltd.Startup	08 Dec 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04231968 (AIRFLO, Pubmed \| N Engl J Med)	Phase 3	Respiratory Syncytial Virus Infections	244	Ziresovir	ipxyovqynk(qwkpfnkrgx) = Resistance-associated mutations were identified in 15 participants (9%) in the ziresovir group vdzygxzcyr (xkuehmtvgk ) View more	Positive	26 Sep 2024
				Placebo
NCT04231968 (AIRFLO, Literature) Manual	Phase 3	Respiratory Syncytial Virus Infections	302	Ziresovir	ylfzsvjmao(rgggpwsjkx) = afhmmuuscw nkmipqthei (bhtfwujgmg, −3.7 - −3.1) View more	Positive	25 Sep 2024
				Placebo	ylfzsvjmao(rgggpwsjkx) = jqonsxveps nkmipqthei (bhtfwujgmg, −3.1 - −2.2) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis